Le Lézard
Classified in: Health, Covid-19 virus
Subject: PDT

DEARhealth Launches AI-powered Chronic Disease Management Platform for Providers in Epic App Orchard


VENICE, Calif., May 27, 2020 /PRNewswire/ -- DEARhealth Inc., a health tech company focused on AI-powered disease management, announced today the global launch of its DEARhealth platform in the Epic App Orchard online marketplace. DEARhealth offers AI-powered care pathways for multiple chronic conditions and integrates with Electronic Medical Records (EMR) systems, giving providers easy access to goal-oriented recommendations. Organizations using Epic, including health systems, hospitals, and clinics, can now access DEARhealth directly through the marketplace instead of traditional external integration, saving significant time, costs, and staff resources.

"Our advanced technology draws on the collective intelligence and experience of medical experts, scientists, and big data analytics to continuously deliver improved health outcomes and control costs in the most complex of chronic diseases," said DEARhealth CEO Dr. Daniel Hommes. "Inclusion in Epic's online marketplace allows DEARhealth to scale across organizations using Epic as their EMR, and we were pleased to work with Epic on achieving this important milestone."

DEARhealth features include:

Epic App Orchard is an online marketplace of solutions certified by Epic Systems for distribution to the Epic community. DEARhealth was approved after a rigorous evaluation process, which included ensuring DEARhealth's software is market-ready, complies with applicable regulations, laws, and privacy protections, and has the appropriate polices in place regarding safety issues, security vulnerabilities, and privacy breaches.

"Integrating new software in healthcare organizations is extremely challenging and can take months to years," said DEARhealth Chief Product Officer Dr. Aria Zand. "Organizations using Epic can now access DEARhealth more quickly, while remaining confident that our solution meets Epic's privacy and security requirements."

"Vast amounts of data are collected in healthcare but we've traditionally lacked the ability to take this data and meaningfully improve individualized patient care," said David Ehrlich, DEARhealth board chairman and CEO of Aktana. "DEARhealth processes this readily available data, and combines scientific evidence, clinical expertise, and AI-driven recommendations to streamline healthcare processes."

About DEARhealth
DEARhealth is a health tech company founded in 2011, by senior University of California, Los Angeles (UCLA) medical experts to transform healthcare by using AI-powered care pathways for chronic disease management. DEARhealth is a validated, AI-driven service that has been successfully implemented in large health systems, in disease areas such as inflammatory bowel diseases, epilepsy, and ovarian cancer. DEARhealth's partners include health systems, providers, payers, and pharmaceutical companies globally. Investors in DEARhealth include Philips Health Technology Ventures, Vesalius Biocapital III, and Health Innovations. To learn more about DEARhealth visit www.dearhealth.com or contact [email protected].

SOURCE DEARhealth, Inc


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: